[go: up one dir, main page]

MX2023011509A - Composiciones vacunales depletantes de factores de crecimiento hematopoyeticos para el tratamiento de enfermedades inflamatorias. - Google Patents

Composiciones vacunales depletantes de factores de crecimiento hematopoyeticos para el tratamiento de enfermedades inflamatorias.

Info

Publication number
MX2023011509A
MX2023011509A MX2023011509A MX2023011509A MX2023011509A MX 2023011509 A MX2023011509 A MX 2023011509A MX 2023011509 A MX2023011509 A MX 2023011509A MX 2023011509 A MX2023011509 A MX 2023011509A MX 2023011509 A MX2023011509 A MX 2023011509A
Authority
MX
Mexico
Prior art keywords
vaccine compositions
treatment
growth factors
inflammatory diseases
hematopoietic growth
Prior art date
Application number
MX2023011509A
Other languages
English (en)
Inventor
Dorantes Gertrudis Rojas
Martínez Dayana Pérez
Dávila Agustín Bienvenido Lage
Naranjo Nuris Ledón
Yáñez Karla Pereira
Sosa Alexa Silva
Morales Dasha Fuentes
Hernandez Danay Saavedra
Alfaro Oscar Otero
Formigo Gisela María Suárez
Valcarcel Jesus Ramón Galvez
Medianilla Armando López
Original Assignee
Ct Inmunologia Molecular
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ct Inmunologia Molecular filed Critical Ct Inmunologia Molecular
Publication of MX2023011509A publication Critical patent/MX2023011509A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001136—Cytokines
    • A61K39/001139—Colony stimulating factors [CSF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/53—Colony-stimulating factor [CSF]
    • C07K14/535—Granulocyte CSF; Granulocyte-macrophage CSF
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6068—Other bacterial proteins, e.g. OMP
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6081—Albumin; Keyhole limpet haemocyanin [KLH]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Organic Chemistry (AREA)
  • Rheumatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

La presente invención se relaciona con la rama de la Biotecnología y la Medicina. Específicamente describe composiciones vacunales terapéuticas capaces de producir una reacción autoinmune contra factores de crecimiento hematopoyéticos como el G-SCF y/o GM-CSF unidas por conjugación química o fusión a otras moléculas o partes de ella. Dichas composiciones vacunales son útiles en el tratamiento de enfermedades inflamatorias, en especial donde ocurra una elevación patológica de neutrófilos circulantes.
MX2023011509A 2021-03-30 2022-03-16 Composiciones vacunales depletantes de factores de crecimiento hematopoyeticos para el tratamiento de enfermedades inflamatorias. MX2023011509A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CU2021000021A CU24734B1 (es) 2021-03-30 2021-03-30 Composicones vacunales depletantes de factores de crecimiento hematopoyéticos para el tratamiento de enfermedades inflamatorias
PCT/CU2022/050002 WO2022207016A1 (es) 2021-03-30 2022-03-16 Composiciones vacunales depletantes de factores de crecimiento hematopoyéticos para el tratamiento de enfermedades inflamatorias

Publications (1)

Publication Number Publication Date
MX2023011509A true MX2023011509A (es) 2023-10-04

Family

ID=81387253

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023011509A MX2023011509A (es) 2021-03-30 2022-03-16 Composiciones vacunales depletantes de factores de crecimiento hematopoyeticos para el tratamiento de enfermedades inflamatorias.

Country Status (14)

Country Link
US (1) US20240374695A1 (es)
EP (1) EP4316510A1 (es)
JP (1) JP2024512762A (es)
KR (1) KR20230163506A (es)
CN (1) CN117120079A (es)
AR (1) AR125149A1 (es)
AU (1) AU2022251604B2 (es)
BR (1) BR112023019112A2 (es)
CA (1) CA3213763A1 (es)
CO (1) CO2023014267A2 (es)
CU (1) CU24734B1 (es)
MX (1) MX2023011509A (es)
TW (1) TW202302623A (es)
WO (1) WO2022207016A1 (es)

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5679356A (en) * 1992-07-08 1997-10-21 Schering Corporation Use of GM-CSF as a vaccine adjuvant
SK782002A3 (en) * 1999-07-21 2003-08-05 Lexigen Pharm Corp FC fusion proteins for enhancing the immunogenicity of protein and peptide antigens
CU23077A1 (es) * 2000-12-06 2005-08-17 Centro Inmunologia Molecular Composicion vacunal que contiene factor de crecimiento transformante (tgf-alfa). su uso en la terapia de enfermedades malignas
CU23297A1 (es) * 2004-11-16 2008-07-24 Ct De Inmunologa A Molecular Formulaciones inmunoterapã0/00uticas para la inducciã"n de autoanticuerpos bloqueadores de la uniã"n de interleucina-2 a su receptor. su uso en el tratamiento del cã ncer
CN102459340A (zh) 2009-04-23 2012-05-16 特罗科隆科学有限公司 粒性白血细胞-巨噬细胞菌落-刺激因子(gm-csf)中和抗体
CN110382532B (zh) * 2017-02-07 2023-04-14 Me医疗公司 抗g-csf抗体及其用途
EP3691663A4 (en) 2017-10-02 2021-08-18 Humanigen, Inc. METHODS OF TREATMENT OF TOXICITY ASSOCIATED WITH IMMUNOTHERAPIES USING A GM-CSF ANTAGONIST
US12281160B2 (en) 2018-03-23 2025-04-22 Csl Limited Method of treating asthma
AU2019393334A1 (en) 2018-12-04 2021-06-10 CSL Innovation Pty Ltd Method of treating neutrophilic conditions

Also Published As

Publication number Publication date
CO2023014267A2 (es) 2024-02-05
AU2022251604B2 (en) 2025-11-27
CA3213763A1 (en) 2022-10-06
CN117120079A (zh) 2023-11-24
AU2022251604A1 (en) 2023-10-26
CU24734B1 (es) 2025-02-07
KR20230163506A (ko) 2023-11-30
AR125149A1 (es) 2023-06-14
WO2022207016A1 (es) 2022-10-06
US20240374695A1 (en) 2024-11-14
JP2024512762A (ja) 2024-03-19
TW202302623A (zh) 2023-01-16
CU20210021A7 (es) 2022-11-07
BR112023019112A2 (pt) 2023-10-24
EP4316510A1 (en) 2024-02-07

Similar Documents

Publication Publication Date Title
Sarsenova et al. Mesenchymal stem cell-based therapy for rheumatoid arthritis
MX2022006854A (es) Composiciones y metodos de arn circular.
EP4501352A3 (en) Compositions and methods for car t cell therapy
BR112013031262A2 (pt) "exotoxinas a de pseudomonas com menos epítopos imunogênicos de célula b e t, e seu uso no tratamento e prevenção de câncer, bem como molécula quimérica, ácido nucleico, vetor de expressão, células, composição farmacêutica e métodos para inibir crescimento de célula-alvo e de produção de endotoxinas a de pseudomonas e de molécula quimérica".
SA522432139B1 (ar) بروتينات ربط متعددة الخصوصية لمعالجة السرطان
WO2019193183A3 (en) Novel yellow fever nucleic acid molecules for vaccination
MX2020010871A (es) Compuestos de 5'-caperuza-trinucleótidos u oligonucleótidos superiores y sus usos en estabilizar arn, que expresan proteínas y en la terapia.
MY200710A (en) Novel fusion protein specific for cd137 and pd-l1
EP4378962A3 (en) Anti-cancer fusion polypeptide
EA201991093A1 (ru) Способ повышения уровней секреции интерлейкина-2 и полученных из него белков
BR102012012673A8 (pt) célula ns0 modificada, métodos de produzir uma proteína recombinante, de obter uma célula hospedeira de mamífero, de sanitizar uma coluna de cromatografia com afinidade para proteína a e de tratar um paciente sofrendo de esclerose múltipla, vetor, composição, processos para colher uma proteína recombinante de uma cultura de célula e para produzir uma composição purificada de daclizumab, meios, e, tampão
ZA202304098B (en) Il-2 mutants and application thereof
WO2017014679A3 (en) Humanized monoclonal antibody specific to syndecan-1
Shyr et al. One year follow-up on the first patient treated with Nula-Cel: an autologous CRISPR/Cas9 gene corrected CD34+ cell product to treat sickle cell disease
MX2022014326A (es) Proteinas multiespecificas.
IN2014CN04734A (es)
WO2022192594A3 (en) Nucleic acid molecules and vaccines comprising same for the prevention and treatment of coronavirus infections and disease
Pînzariu et al. The therapeutic use and potential of MSCs: advances in regenerative medicine
MX2024007160A (es) Composiciones de arnm inmuno-estimuladoras y usos de las mismas.
MX2025001093A (es) Moleculas de union al antigeno biespecificas anti-c-kit y anti-cd203c y usos de estas
MX2023011509A (es) Composiciones vacunales depletantes de factores de crecimiento hematopoyeticos para el tratamiento de enfermedades inflamatorias.
MX2021008507A (es) Moleculas que se unen al receptor leucocitario similar a inmunoglobulina subfamilia b miembro 3 (lilrb3) y usos para las mismas.
PH12018500058A1 (en) Fusion molecules
WO2022236276A3 (en) Anti-tigit antibodies, anti-cd96 antibodies, and methods of use thereof
Singpant et al. Recombinant Cas9 protein production in an endotoxin-free system and evaluation with editing the BCL11A gene in human cells